???global.info.a_carregar???
Identification

Personal identification

Full name
António Medina de Almeida

Citation names

  • Almeida, António
  • Antonio M Almeida
  • Antonio Medina de Almeida

Author identifiers

Ciência ID
2916-FA5B-A9F2
ORCID iD
0000-0003-4361-0928

Languages

Language Speaking Reading Writing Listening Peer-review
Portuguese (Mother tongue)
English Proficiency (C2) Proficiency (C2) Proficiency (C2) Proficiency (C2) Proficiency (C2)
Spanish; Castilian Advanced (C1) Advanced (C1) Upper intermediate (B2) Advanced (C1) Advanced (C1)
Italian Proficiency (C2) Proficiency (C2) Advanced (C1) Proficiency (C2) Proficiency (C2)
French Advanced (C1) Advanced (C1) Upper intermediate (B2) Advanced (C1) Advanced (C1)
Education
Degree Classification
2021/04/14
Concluded
 Agregação (Título de Agregado)
Major in Ciencias da Saude
Universidade Católica Portuguesa, Portugal
 Aprovado
2003/06/01 - 2007/05/01
Concluded
 PhD Medicine (Doktor (PhD))
Major in Hematology
Imperial College London, United Kingdom
"Biochemical and Molecular Characterization of Inherited GPI Deficiency" (THESIS/DISSERTATION)
 pass
1988/10/01 - 1993/12/10
Concluded
 MB BChir (Bachelor)
Major in Medicina
University of Cambridge Medical Library, United Kingdom
 2.2
Affiliation

Teaching in Higher Education

Category
Host institution 		Employer
2023/02/07 - Current Full Professor (University Teacher) Universidade Católica Portuguesa, Portugal
Universidade Católica Portuguesa, Portugal
2021/09/01 - 2023/02/07 Associate Professor (University Teacher) Universidade Católica Portuguesa, Portugal
2016 - 2019 Invited Assistant Professor (University Teacher) Universidade Nova de Lisboa, Portugal
2014 - 2016 Assistant Professor (University Teacher) Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal
2013 - 2014 Assistant (University Teacher) Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal
Outputs

Publications

Journal article
  1. Francois-Xavier Mahon; Markus Pfirrmann; Stéphanie Dulucq; Andreas Hochhaus; Panayiotis Panayiotidis; Antonio Almeida; Jiri Mayer; et al. "European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission". Journal of Clinical Oncology (2024): https://doi.org/10.1200/JCO.23.01647.
    10.1200/JCO.23.01647
  2. Fioredda, Francesca; Skokowa, Julia; Tamary, Hannah; Spanoudakis, Michail; Farruggia, Piero; Almeida, Antonio; Guardo, Daniela; et al. "The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children: A Consensus Between the European Hematology Association and the EuNet-INNOCHRON COST Action". HemaSphere 7 4 (2023): e872. http://dx.doi.org/10.1097/hs9.0000000000000872.
    Published • 10.1097/hs9.0000000000000872
  3. Wondergem, Marielle J.; Almeida, Antonio; Brolin, Janaki; Fernandez de Larrea, Carlos; van Havre, Nathalie; Hemker, Bas T.; Hollegien, Wietske; et al. "The Progress Test of the European Hematology Association: A New Tool for Continuous Learning". HemaSphere 6 12 (2022): e815. http://dx.doi.org/10.1097/hs9.0000000000000815.
    Published • 10.1097/hs9.0000000000000815
  4. Alves, Raquel; Gonçalves, Ana Cristina; Jorge, Joana; Marques, Gilberto; Ribeiro, André B.; Tenreiro, Rita; Coucelo, Margarida; et al. "Genetic Variants of ABC and SLC Transporter Genes and Chronic Myeloid Leukaemia: Impact on Susceptibility and Prognosis". International Journal of Molecular Sciences 23 17 (2022): 9815. http://dx.doi.org/10.3390/ijms23179815.
    Published • 10.3390/ijms23179815
  5. Alves, Raquel; Gonçalves, Ana Cristina; Jorge, Joana; Almeida, António M.; Sarmento-Ribeiro, Ana Bela. "Combination of Elacridar with Imatinib Modulates Resistance Associated with Drug Efflux Transporters in Chronic Myeloid Leukemia". Biomedicines 10 5 (2022): 1158. http://dx.doi.org/10.3390/biomedicines10051158.
    Published • 10.3390/biomedicines10051158
  6. Raquel Alves; Ana Cristina Gonçalves; Sergio Rutella; António M. Almeida; Javier De Las Rivas; Ioannis Trougakos; Ana Bela Sarmento Ribeiro. "Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance". Cancers 13 19 (2021): 4820-4820. http://dx.doi.org/10.3390/cancers13194820.
    10.3390/cancers13194820
  7. Filipa Lopes-Coelho; Filipa Martins; Ana Hipólito; Cindy Mendes; Catarina O. Sequeira; Rita F. Pires; António M. Almeida; et al. "The Activation of Endothelial Cells Relies on a Ferroptosis-Like Mechanism: Novel Perspectives in Management of Angiogenesis and Cancer Therapy". Frontiers in Oncology 11 (2021): http://dx.doi.org/10.3389/fonc.2021.656229.
    10.3389/fonc.2021.656229
  8. Guillermo Garcia-Manero; VALERIA SANTINI; Antonio Almeida; Uwe Platzbecker; Anna Jonasova; Lewis R. Silverman; Jose Falantes; et al. "Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes". Journal of Clinical Oncology 39 13 (2021): 1426-1436. http://dx.doi.org/10.1200/jco.20.02619.
    10.1200/jco.20.02619
  9. Lisa Pleyer; Michael Leisch; Alexandra Kourakli; Eric Padron; Jaroslaw Pawel Maciejewski; Blanca Xicoy Cirici; Jennifer Kaivers; et al. "Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study". The Lancet Haematology 8 2 (2021): e135-e148. http://dx.doi.org/10.1016/s2352-3026(20)30374-4.
    10.1016/s2352-3026(20)30374-4
  10. Ludovic Lhermitte; Sylvain Barreau; Daniela Morf; Paula Fernandez; Georgiana Grigore; Susana Barrena; Maaike de Bie; et al. "Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study". Modern Pathology 34 1 (2021): 59-69. http://dx.doi.org/10.1038/s41379-020-00677-7.
    10.1038/s41379-020-00677-7
  11. Joana Infante; Andre Casado; Antonio Almeida; Antonio Messias. "Spontaneous Tumor Lysis Syndrome: A Rare Presentation in Plasmablastic Lymphoma". Journal of Hematology 10 1 (2021): 30-34. http://dx.doi.org/10.14740/jh620.
    10.14740/jh620
  12. "Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.". The New England journal of medicine (2020): https://doi.org/10.1056/NEJMoa2004444.
    10.1056/nejmoa2004444
  13. Theo De Witte; Luca Malcovati; Pierre Fenaux; David Bowen; Argiris Symeonidis; Moshe Mittelman; Reinhard Stauder; et al. "Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective". Haematologica 105 11 (2020): 2516-2523. http://dx.doi.org/10.3324/haematol.2020.266817.
    10.3324/haematol.2020.266817
  14. "Guideline-based indicators for adult patients with myelodysplastic syndromes.". Blood advances (2020): https://europepmc.org/articles/PMC7448599.
    10.1182/bloodadvances.2020002314
  15. "Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients.". Leukemia (2020): https://doi.org/10.1038/s41375-020-0961-3.
    10.1038/s41375-020-0961-3
  16. "Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels.". Leukemia & lymphoma (2020): https://doi.org/10.1080/10428194.2020.1719088.
    10.1080/10428194.2020.1719088
  17. "Monocytes as Endothelial Progenitor Cells (EPCs), Another Brick in the Wall to Disentangle Tumor Angiogenesis.". Cells (2020): https://europepmc.org/articles/PMC7016533.
    10.3390/cells9010107
  18. "Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available.". Leukemia & lymphoma (2019): https://doi.org/10.1080/10428194.2019.1636985.
    10.1080/10428194.2019.1636985
  19. "Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry.". Haematologica (2019): https://europepmc.org/articles/PMC7049356.
    10.3324/haematol.2018.212332
  20. "Negative MR4·0 chronic myeloid leukaemia and its possible implications for treatment-free remission.". British journal of haematology (2019): https://doi.org/10.1111/bjh.16058.
    10.1111/bjh.16058
  21. "Less iron improves MDS haematopoiesis.". British journal of haematology (2019): https://doi.org/10.1111/bjh.16012.
    10.1111/bjh.16012
  22. Bruno A. Cardoso; Teresa L. Ramos; Hélio Belo; Filipe Vilas-Boas; Carla Real; António M. Almeida. "Vorinostat synergizes with antioxidant therapy to target myeloproliferative neoplasms". Experimental Hematology 72 (2019): 60-71.e11. https://doi.org/10.1016/j.exphem.2019.02.002.
    10.1016/j.exphem.2019.02.002
  23. Guillermo Garcia-Manero; Antonio Almeida; Pierre Fenaux; Norbert Gattermann; Aristoteles Giagounidis; Stuart L. Goldberg; Keiya Ozawa; Jerry Weaver; Valeria Santini. "Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial". Clinical Lymphoma Myeloma and Leukemia 19 4 (2019): 213-219.e4. https://doi.org/10.1016/j.clml.2018.12.012.
    10.1016/j.clml.2018.12.012
  24. "Everolimus in combination with Imatinib overcomes resistance in Chronic myeloid leukaemia.". Medical oncology (Northwood, London, England) (2019): https://doi.org/10.1007/s12032-019-1253-5.
    10.1007/s12032-019-1253-5
  25. "New prospects for the management of cardiovascular effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemia.". Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology (2019): https://doi.org/10.1016/j.repc.2017.10.013.
    10.1016/j.repc.2017.10.013
  26. "Evidence-Based Criteria for Tyrosine Kinase Inhibitor Interruption in Pregnancy.". Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018): https://doi.org/10.1200/JCO.18.00814.
    10.1200/jco.18.00814
  27. "Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes.". Blood advances (2018): https://europepmc.org/articles/PMC6113605.
    10.1182/bloodadvances.2018020495
  28. "Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia.". Blood advances (2018): https://europepmc.org/articles/PMC6113613.
    10.1182/bloodadvances.2018015529
  29. Antonio Almeida. "Should more MDS patients be treated with immune-suppression?". Leukemia Research 71 (2018): 25-26. https://doi.org/10.1016/j.leukres.2018.06.011.
    10.1016/j.leukres.2018.06.011
  30. Giuseppe Saglio; Giora Sharf; Antonio Almeida; Andrija Bogdanovic; Felice Bombaci; Jelena Cugurovic; Nigel Deekes; et al. "Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient–Physician Perspective". Clinical Lymphoma Myeloma and Leukemia 18 6 (2018): 375-379. https://doi.org/10.1016/j.clml.2018.04.005.
    10.1016/j.clml.2018.04.005
  31. A. Almeida. "Hematology traning in Europe". International Journal of Laboratory Hematology 40 (2018): 137-138. https://doi.org/10.1111/ijlh.12815.
    10.1111/ijlh.12815
  32. Falantes, J.; Pleyer, L.; Thépot, S.; Almeida, A.M.; Maurillo, L.; Martínez-Robles, V.; Stauder, R.; et al. "Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+)". Leukemia and Lymphoma (2017): 1-8. http://www.scopus.com/inward/record.url?eid=2-s2.0-85028547438&partnerID=MN8TOARS.
    10.1080/10428194.2017.1365854
  33. Almeida, A.; Fenaux, P.; List, A.F.; Raza, A.; Platzbecker, U.; Santini, V.. "Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS)". Leukemia Research 52 (2017): 50-57. http://www.scopus.com/inward/record.url?eid=2-s2.0-84995948190&partnerID=MN8TOARS.
    10.1016/j.leukres.2016.11.008
  34. Urbano-Ispizua, Á.; Muus, P.; Schrezenmeier, H.; Almeida, A.M.; Wilson, A.; Ware, R.E.. "Different clinical characteristics of paroxysmal nocturnal hemoglobinuria in pediatric and adult patients". Haematologica 102 3 (2017): e76-e79. http://www.scopus.com/inward/record.url?eid=2-s2.0-85014431908&partnerID=MN8TOARS.
    10.3324/haematol.2016.151852
  35. Almeida, A.M.; Prebet, T.; Itzykson, R.; Ramos, F.; Al-Ali, H.; Shammo, J.; Pinto, R.; et al. "Clinical outcomes of 217 patients with acute erythroleukemia according to treatment type and line: A retrospective multinational study". International Journal of Molecular Sciences 18 4 (2017): http://www.scopus.com/inward/record.url?eid=2-s2.0-85018470782&partnerID=MN8TOARS.
    10.3390/ijms18040837
  36. Almeida, A.M.; Bedrosian, C.; Cole, A.; Muus, P.; Schrezenmeier, H.; Szer, J.; Rosse, W.F.. "Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry". Internal Medicine Journal 47 9 (2017): 1026-1034. http://www.scopus.com/inward/record.url?eid=2-s2.0-85029028390&partnerID=MN8TOARS.
    10.1111/imj.13523
  37. Almeida, A.; Ferreira, A.R.; Costa, M.J.; Silva, S.; Alnajjar, K.; Bogalho, I.; Pierdomenico, F.; et al. "Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study". Leukemia Research Reports 7 (2017): 6-10. http://www.scopus.com/inward/record.url?eid=2-s2.0-85008625228&partnerID=MN8TOARS.
    10.1016/j.lrr.2016.12.002
  38. Ramos, T.L.; Sánchez-Abarca, L.I.; Redondo, A.; Hernández-Hernández, Á.; Almeida, A.M.; Puig, N.; Rodríguez, C.; et al. "HDAC8 overexpression in mesenchymal stromal cells from JAK2+myeloproliferative neoplasms: A new therapeutic target?". Oncotarget 8 17 (2017): 28187-28202. http://www.scopus.com/inward/record.url?eid=2-s2.0-85018445911&partnerID=MN8TOARS.
    10.18632/oncotarget.15969
  39. Garcia-Manero, G.; Almeida, A.; Giagounidis, A.; Platzbecker, U.; Garcia, R.; Voso, M.T.; Larsen, S.R.; et al. "Design and rationale of the QUAZAR lower-risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion–dependent anemia and thrombocytopenia". BMC Hematology 16 1 (2016): http://www.scopus.com/inward/record.url?eid=2-s2.0-85013354216&partnerID=MN8TOARS.
    10.1186/s12878-016-0049-5
  40. Santini, V.; Almeida, A.; Giagounidis, A.; Gröpper, S.; Jonasova, A.; Vey, N.; Mufti, G.J.; et al. "Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents". Journal of Clinical Oncology 34 25 (2016): 2988-2996. http://www.scopus.com/inward/record.url?eid=2-s2.0-84983628285&partnerID=MN8TOARS.
    10.1200/JCO.2015.66.0118
  41. Almeida, A.M.; Ramos, F.. "Acute myeloid leukemia in the older adults". Leukemia Research Reports 6 (2016): 1-7. http://www.scopus.com/inward/record.url?eid=2-s2.0-84976312717&partnerID=MN8TOARS.
    10.1016/j.lrr.2016.06.001
  42. Roboz, G.J.; Montesinos, P.; Selleslag, D.; Wei, A.; Jang, J.-H.; Falantes, J.; Voso, M.T.; et al. "Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia". Future Oncology 12 3 (2016): 293-302. http://www.scopus.com/inward/record.url?eid=2-s2.0-84961348336&partnerID=MN8TOARS.
    10.2217/fon.15.326
  43. Cardoso, B.A.; Belo, H.; Barata, J.T.; Almeida, A.M.. "The bone marrow-mediated protection of myeloproliferative neoplastic cells to vorinostat and ruxolitinib relies on the activation of JNK and PI3K Signalling Pathways". PLoS ONE 10 12 (2015): http://www.scopus.com/inward/record.url?eid=2-s2.0-84957108370&partnerID=MN8TOARS.
    10.1371/journal.pone.0143897
  44. Belo, H.; Silva, G.; Cardoso, B.A.; Porto, B.; Minguillon, J.; Barbot, J.; Coutinho, J.; et al. "Epigenetic Alterations in Fanconi anaemia: Role in pathophysiology and therapeutic potential". PLoS ONE 10 10 (2015): http://www.scopus.com/inward/record.url?eid=2-s2.0-84949034122&partnerID=MN8TOARS.
    10.1371/journal.pone.0139740
  45. de Swart, L.; Smith, A.; Johnston, T.W.; Haase, D.; Droste, J.; Fenaux, P.; Symeonidis, A.; et al. "Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry". British Journal of Haematology 170 3 (2015): 372-383. http://www.scopus.com/inward/record.url?eid=2-s2.0-84942121801&partnerID=MN8TOARS.
    10.1111/bjh.13450
  46. Belo, Hélio José Loureno Miguens Rodrigues; Silva, Gabriela; Cardoso, Bruno; Porto, Beatriz; Minguillon, Jordi; Casado, Jorge; Almeida, António Medina de. "Epigenetic alterations in Fanconi Anaemia: Role in pathophysiology and therapeutic potential". (2015): http://hdl.handle.net/10362/21493.
    https://doi.org/10.1371/journal.pone.0139740
  47. Almeida, António Medina de; Belo, Hélio José Loureno Miguens Rodrigues; Cardoso, Bruno António Caetano. "The bone marrow-mediated protection of myeloproliferative neoplastic cells to Vorinostat and Ruxolitinib relies on the activation of JNK and PI3K signalling pathways". (2015): http://hdl.handle.net/10362/21495.
    https://doi.org/10.1371/journal.pone.0143897
  48. Almeida, A.M.. "Optimizing treatments in rare diseases: Will our evidence come from registry data?". Leukemia Research 38 4 (2014): 421-422. http://www.scopus.com/inward/record.url?eid=2-s2.0-84897109389&partnerID=MN8TOARS.
    10.1016/j.leukres.2014.01.015
  49. Costa, J.R.; Caputo, V.S.; Makarona, K.; Layton, D.M.; Roberts, I.A.G.; Almeida, A.M.; Karadimitris, A.. "Cell-type-specific transcriptional regulation of PIGM underpins the divergent hematologic phenotype in inherited GPl deficiency". Blood 124 20 (2014): 3151-3154. http://www.scopus.com/inward/record.url?eid=2-s2.0-84911394061&partnerID=MN8TOARS.
    10.1182/blood-2014-09-598813
  50. Silva, G.; Cardoso, B.A.; Belo, H.; Almeida, A.M.. "Vorinostat Induces Apoptosis and Differentiation in Myeloid Malignancies: Genetic and Molecular Mechanisms". PLoS ONE 8 1 (2013): http://www.scopus.com/inward/record.url?eid=2-s2.0-84872172430&partnerID=MN8TOARS.
    10.1371/journal.pone.0053766
  51. Pierdomenico, F.; Esteves, S.; Almeida, A.. "Efficacy and tolerability of 5-day azacytidine dose-intensified regimen in higher-risk MDS". Annals of Hematology 92 9 (2013): 1201-1206. http://www.scopus.com/inward/record.url?eid=2-s2.0-84883134397&partnerID=MN8TOARS.
    10.1007/s00277-013-1762-9
  52. Almeida, A.. "Modifying disease in CMML: Who responds to Azacitidine?". Leukemia Research 37 6 (2013): 603-604. http://www.scopus.com/inward/record.url?eid=2-s2.0-84877035170&partnerID=MN8TOARS.
    10.1016/j.leukres.2013.02.004
  53. Pierdomenico, F.; Almeida, A.. "Treatment of acute erythroleukemia with Azacitidine: A case series". Leukemia Research Reports 2 2 (2013): 41-43. http://www.scopus.com/inward/record.url?eid=2-s2.0-84887558081&partnerID=MN8TOARS.
    10.1016/j.lrr.2013.04.001
  54. Thorpe, M.; Montalvão, A.; Pierdomenico, F.; Moita, F.; Almeida, A.. "Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: A case series and literature review". Leukemia Research 36 8 (2012): 1071-1073. http://www.scopus.com/inward/record.url?eid=2-s2.0-84862513949&partnerID=MN8TOARS.
    10.1016/j.leukres.2012.04.024
  55. Almeida, A.M.; Pierdomenico, F.. "Generalized skin reactions in patients with MDS and CMML treated with azacitidine: Effective management with concomitant prednisolone". Leukemia Research 36 9 (2012): http://www.scopus.com/inward/record.url?eid=2-s2.0-84864002826&partnerID=MN8TOARS.
    10.1016/j.leukres.2012.04.029
  56. Nolte, F.; Angelucci, E.; Beris, P.; Macwhannell, A.; Selleslag, D.; Schumann, C.; Xicoy, B.; et al. "Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox". Leukemia Research 35 9 (2011): 1131-1135. http://www.scopus.com/inward/record.url?eid=2-s2.0-80051475539&partnerID=MN8TOARS.
    10.1016/j.leukres.2011.06.013
  57. Almeida, A.; Layton, M.; Karadimitris, A.. "Chapter 16 Inherited GPI deficiency". Enzymes 26 C (2009): 357-373. http://www.scopus.com/inward/record.url?eid=2-s2.0-77954852055&partnerID=MN8TOARS.
    10.1016/S1874-6047(09)26016-1
  58. Almeida, A.; Castro, I.; Coutinho, J.; Guerra, L.; Marques, H.; Pereira, A.M.. "Recommendations for diagnosis, treatment and monitoring of chronic myeloid leukemia | Recomendações para o diagnóstico, tratamento e monitorização da leucemia mielóide crónica". Acta Medica Portuguesa 22 5 (2009): 537-544. http://www.scopus.com/inward/record.url?eid=2-s2.0-77149124911&partnerID=MN8TOARS.
  59. Almeida, A.; Layton, M.; Karadimitris, A.. "Inherited glycosylphosphatidyl inositol deficiency: A treatable CDG". Biochimica et Biophysica Acta - Molecular Basis of Disease 1792 9 (2009): 874-880. http://www.scopus.com/inward/record.url?eid=2-s2.0-70249117159&partnerID=MN8TOARS.
    10.1016/j.bbadis.2008.12.010
  60. Almeida, A.M.; Murakami, Y.; Baker, A.; Maeda, Y.; Roberts, I.A.G.; Kinoshita, T.; Layton, D.M.; Karadimitris, A.. "Targeted therapy for inherited GPI deficiency". New England Journal of Medicine 356 16 (2007): 1641-1647. http://www.scopus.com/inward/record.url?eid=2-s2.0-34247229178&partnerID=MN8TOARS.
    10.1056/NEJMoa063369
  61. Almeida, A.M.; Murakami, Y.; Layton, D.M.; Hillmen, P.; Sellick, G.S.; Maeda, Y.; Richards, S.; et al. "Hypomorphic promoter mutation in PIGM causes inherited glycosylphosphatidylinositol deficiency". Nature Medicine 12 7 (2006): 846-851. http://www.scopus.com/inward/record.url?eid=2-s2.0-33745904714&partnerID=MN8TOARS.
    10.1038/nm1410
  62. Kotsianidis, I.; Silk, J.D.; Spanoudakis, E.; Patterson, S.; Almeida, A.; Schmidt, R.R.; Tsatalas, C.; et al. "Regulation of hematopoiesis in vitro and in vivo by invariant NKT cells". Blood 107 8 (2006): 3138-3144. http://www.scopus.com/inward/record.url?eid=2-s2.0-33645731424&partnerID=MN8TOARS.
    10.1182/blood-2005-07-2804
  63. Patterson, S.; Kotsianidis, I.; Almeida, A.; Politou, M.; Rahemtulla, A.; Matthew, B.; Schmidt, R.R.; et al. "Human invariant NKT cells are required for effective in vitro alloresponses". Journal of Immunology 175 8 (2005): 5087-5094. http://www.scopus.com/inward/record.url?eid=2-s2.0-26844497901&partnerID=MN8TOARS.
  64. Almeida, A.; Roberts, I.. "Bone involvement in sickle cell disease". British Journal of Haematology 129 4 (2005): 482-490. http://www.scopus.com/inward/record.url?eid=2-s2.0-20044374216&partnerID=MN8TOARS.
    10.1111/j.1365-2141.2005.05476.x
  65. Henthorn, J.S.; Almeida, A.M.; Davies, S.C.. "Neonatal screening for sickle cell disorders". British Journal of Haematology 124 3 (2004): 259-263. http://www.scopus.com/inward/record.url?eid=2-s2.0-0842287208&partnerID=MN8TOARS.
    10.1046/j.1365-2141.2003.04775.x
  66. Daniel, Y.; Witchlow, B.; Almeida, A.. "Automated computer result reporting for haemoglobinopathy screening". Clinical and Laboratory Haematology 26 1 (2004): 21-24. http://www.scopus.com/inward/record.url?eid=2-s2.0-1242272706&partnerID=MN8TOARS.
    10.1111/j.0141-9854.2003.00580.x
  67. "The use of recombinant factor VIIa in children with inherited platelet function disorders.". British journal of haematology (2003): https://doi.org/10.1046/j.1365-2141.2003.04286.x.
    10.1046/j.1365-2141.2003.04286.x
  68. Amrolia, P.J.; Almeida, A.; Halsey, C.; Roberts, I.A.G.; Davies, S.C.. "Therapeutic challenges in childhood sickle cell disease Part 1: Current and future treatment options". British Journal of Haematology 120 5 (2003): 725-736. http://www.scopus.com/inward/record.url?eid=2-s2.0-0037335688&partnerID=MN8TOARS.
    10.1046/j.1365-2141.2003.04143.x
  69. Amrolia, P.J.; Almeida, A.; Davies, S.C.; Roberts, I.A.G.. "Therapeutic challenges in childhood sickle cell disease. Part 2: A problem-orientated approach". British Journal of Haematology 120 5 (2003): 737-743. http://www.scopus.com/inward/record.url?eid=2-s2.0-0037338359&partnerID=MN8TOARS.
    10.1046/j.1365-2141.2003.04144.x
  70. Hunt, B.J.; Gattens, M.; Khamashta, M.; Nelson-Piercy, C.; Almeida, A.. "Thromboprophylaxis with unmonitored intermediate-dose low molecular weight heparin in pregnancies with a previous arterial or venous thrombotic event.". Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 14 8 (2003): 735-739. http://www.scopus.com/inward/record.url?eid=2-s2.0-14844328732&partnerID=MN8TOARS.
    10.1097/00001721-200312000-00007
  71. Almeida, A.; Khair, K.; Hann, I.; Liesner, R.. "Unusual presentation of factor XIII deficiency". Haemophilia 8 5 (2002): 703-705. http://www.scopus.com/inward/record.url?eid=2-s2.0-0036736431&partnerID=MN8TOARS.
  72. Almeida, A.M.; Henthorn, J.S.; Davies, S.C.. "Neonatal screening for haemoglobinopathies: The results of a 10-year programme in an English Health Region". British Journal of Haematology 112 1 (2001): 32-35. http://www.scopus.com/inward/record.url?eid=2-s2.0-0035133830&partnerID=MN8TOARS.
    10.1046/j.1365-2141.2001.02512.x
  73. McCloy, M.; Almeida, A.; Daly, P.; Vulliamy, T.; Roberts, I.A.G.; Dokal, I.. "Fludarabine-based stem cell transplantation protocol for Fanconi's anaemia in myelodysplastic transformation". British Journal of Haematology 112 2 (2001): 427-429. http://www.scopus.com/inward/record.url?eid=2-s2.0-0035127488&partnerID=MN8TOARS.
    10.1046/j.1365-2141.2001.02585.x
Thesis / Dissertation
  1. Nolasco, Madalena Tavares Festas de Sousa. "Controlo transcricional de PIGM:mecanismo de expressão diferencial em células sanguíneas na insuficiência hereditária de GPI". Master, 2009. http://catalogo.ul.pt/F/?func=item-global&doc_library=ULB01&type=03&doc_number=000576082.
Activities

Association member

Society Organization name Role
2023 - Current Grupo Português de Leucemia Mielóide Crónica (Portuguese CML group) National Coordinator
2019 - Current COSMYD: European myeloproliferative group Member
2016 - Current Grupo Português de Mielodisplasias (Portuguese MDS group) Member
2016 - Current American Society for Haematology Member
2015 - Current EUTOS European CML registry National Coordinator
2014 - Current International PNH registry National Coordinator
2014 - Current European LeukemiaNet Member
2013 - Current European Haematology Association President

Journal scientific committee

Journal title (ISSN) Publisher
2017 - Current Leukemia Research Reports (2213-0489) Elsevier
2015 - Current Leukemia Research (1873-5835) Elsevier
2015 - Current Oncotarget (1949-2553) Impact Journals, LLC
2014 - Current Plos One (1932-6203) PLOS
2014 - Current Haematologica (1592-8721)